NeoRich BioPharma Tech Co., Limited
PHBID
$0.45
-$0.43-49.28%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 800.00 | 500.00 | 600.00 | 1.10K | 1.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 800.00 | 500.00 | 600.00 | 1.10K | 1.20K |
| Cost of Revenue | 500.00 | 400.00 | 500.00 | 300.00 | 500.00 |
| Gross Profit | 400.00 | 100.00 | 100.00 | 700.00 | 800.00 |
| SG&A Expenses | 61.80K | 50.50K | 57.20K | 66.20K | 76.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.30K | 50.90K | 57.70K | 66.60K | 76.50K |
| Operating Income | -61.40K | -50.40K | -57.10K | -65.50K | -75.20K |
| Income Before Tax | 633.30K | -779.10K | -42.60K | -38.00K | -144.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 633.30K | -779.10K | -42.60K | -38.00K | -144.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 0.00 | -- | -- |
| Net Income | 633.30K | -779.10K | -42.50K | -38.00K | -144.90K |
| EBIT | -61.40K | -50.40K | -57.10K | -65.50K | -75.20K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 1.91 | -2.35 | -0.13 | -0.11 | -0.45 |
| Normalized Basic EPS | 1.19 | -1.47 | -0.08 | -0.07 | -0.28 |
| EPS Diluted | 1.91 | -2.35 | -0.13 | -0.11 | -0.45 |
| Normalized Diluted EPS | 1.19 | -1.47 | -0.08 | -0.07 | -0.28 |
| Average Basic Shares Outstanding | 331.80K | 331.80K | 331.80K | 331.80K | 323.30K |
| Average Diluted Shares Outstanding | 331.80K | 331.80K | 331.80K | 331.80K | 323.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |